FR2854073B1 - Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre - Google Patents

Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre

Info

Publication number
FR2854073B1
FR2854073B1 FR0450692A FR0450692A FR2854073B1 FR 2854073 B1 FR2854073 B1 FR 2854073B1 FR 0450692 A FR0450692 A FR 0450692A FR 0450692 A FR0450692 A FR 0450692A FR 2854073 B1 FR2854073 B1 FR 2854073B1
Authority
FR
France
Prior art keywords
pharmaceutical composition
receptor agonist
sugar alcohol
solid pharmaceutical
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0450692A
Other languages
English (en)
French (fr)
Other versions
FR2854073A1 (fr
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Colleen Ruegger
Alan Edward Royce
Masaki Sasaki
Tokuhiro Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Tanabe Pharma Corp
Original Assignee
Novartis AG
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2854073(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Mitsubishi Pharma Corp filed Critical Novartis AG
Publication of FR2854073A1 publication Critical patent/FR2854073A1/fr
Application granted granted Critical
Publication of FR2854073B1 publication Critical patent/FR2854073B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
FR0450692A 2003-04-08 2004-04-06 Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre Expired - Lifetime FR2854073B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (2)

Publication Number Publication Date
FR2854073A1 FR2854073A1 (fr) 2004-10-29
FR2854073B1 true FR2854073B1 (fr) 2008-03-14

Family

ID=32326722

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (fr) 2003-04-08 2004-04-06 Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre
FR11C0036C Active FR11C0036I2 (fr) 2003-04-08 2011-09-08 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR11C0036C Active FR11C0036I2 (fr) 2003-04-08 2011-09-08 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Country Status (41)

Country Link
US (11) US20060275357A1 (enExample)
EP (5) EP2008650A3 (enExample)
JP (3) JP5495467B2 (enExample)
KR (3) KR20110005320A (enExample)
CN (2) CN101797241B (enExample)
AR (3) AR043987A1 (enExample)
AT (3) ATE414508T1 (enExample)
AU (1) AU2004228929B2 (enExample)
BE (2) BE1015972A5 (enExample)
BR (1) BRPI0409250B8 (enExample)
CA (2) CA2521325C (enExample)
CL (2) CL2004000745A1 (enExample)
CY (3) CY1110260T1 (enExample)
DE (4) DE202004021680U1 (enExample)
DK (2) DK1613288T3 (enExample)
EC (1) ECSP056090A (enExample)
ES (3) ES2556947T3 (enExample)
FR (2) FR2854073B1 (enExample)
GB (1) GB2400318B (enExample)
GR (1) GR1005052B (enExample)
HR (3) HRP20050886B1 (enExample)
HU (2) HUE028247T2 (enExample)
IL (3) IL170888A (enExample)
IS (2) IS2682B (enExample)
IT (1) ITMI20040682A1 (enExample)
LU (1) LU91867I2 (enExample)
MA (1) MA27729A1 (enExample)
MX (1) MXPA05010860A (enExample)
MY (1) MY141249A (enExample)
NO (4) NO329332B1 (enExample)
NZ (3) NZ542622A (enExample)
PE (5) PE20050396A1 (enExample)
PL (2) PL2316431T3 (enExample)
PT (1) PT1613288E (enExample)
RU (5) RU2358716C2 (enExample)
SG (1) SG175449A1 (enExample)
SI (2) SI1613288T1 (enExample)
TN (1) TNSN05256A1 (enExample)
TW (1) TWI332847B (enExample)
WO (1) WO2004089341A1 (enExample)
ZA (1) ZA200507394B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
DK2295049T3 (en) * 2005-09-09 2015-02-23 Novartis Ag Treatment of autoimmune diseases
CA2629084C (en) 2005-11-09 2015-08-11 Proteolix, Inc. Compounds for inhibition of chymotrypsin-like activity of the 20s proteasome
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ603303A (en) 2006-06-19 2014-05-30 Onyx Therapeutics Inc Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
WO2008037421A2 (en) * 2006-09-26 2008-04-03 Novartis Ag Pharmaceutical compositions comprising an s1p modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
AU2008241982B2 (en) 2007-03-29 2013-02-21 Daiichi Sankyo Company, Limited Pharmaceutical composition
HRP20160808T4 (hr) 2007-10-04 2020-05-29 Onyx Therapeutics, Inc. Kristalni paptidi epoksiketona kao inhibitori proteaze i sinteza ketoepoksidnih aminokiselina
KR20170021904A (ko) 2007-10-12 2017-02-28 노파르티스 아게 스핑고신 1 포스페이트 (ｓ1ｐ) 수용체 조절제를 포함하는 조성물
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
MY177360A (en) 2008-03-17 2020-09-14 Actelion Pharmaceuticals Ltd Dosing regimen for aselective s1p1 receptor agonist
US11166917B2 (en) * 2008-06-20 2021-11-09 Merck Patent Gmbh Direct injection moldable and rapidly disintegrating tablet matrix
KR20180017232A (ko) 2008-06-20 2018-02-20 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
PL2334202T3 (pl) * 2008-09-04 2012-04-30 Cargill Inc Tabletkowanie erytrytolu
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
AU2013100533B4 (en) * 2008-11-11 2013-12-12 Novartis Ag Crystalline forms of fingolimod HCL
WO2010055027A2 (en) 2008-11-11 2010-05-20 Novartis Ag Organic compounds
RU2015111229A (ru) * 2008-11-11 2015-11-20 Новартис Аг Кристаллические формы гидрохлорида финголимода
HRP20131109T1 (hr) 2008-12-17 2014-01-31 Daiichi Sankyo Company, Limited Postupak proizvodnje derivata diamina
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
EP2407450B1 (en) 2009-03-13 2015-04-22 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
ES2605034T3 (es) * 2009-06-18 2017-03-10 Daiichi Sankyo Company, Limited Composición farmacéutica con solubilidad mejorada
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
JP6042724B2 (ja) 2010-03-01 2016-12-14 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． イムノプロテアソーム阻害のための化合物
CA2793413C (en) 2010-03-19 2015-11-24 Daiichi Sankyo Company, Limited Crystal form of edoxaban tosylate monohydrate and method of producing same
KR101792299B1 (ko) 2010-03-19 2017-10-31 다이이찌 산쿄 가부시키가이샤 항응고제의 용출 개선 방법
CA2797029A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
HUE031961T2 (en) 2010-07-02 2017-09-28 Daiichi Sankyo Co Ltd A method for preparing an optically active salt of diamine derivative
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
ES2751920T3 (es) 2011-01-07 2020-04-02 Novartis Ag Formulaciones inmunosupresoras
ES2662373T3 (es) 2011-01-19 2018-04-06 Pathologica, Llc. Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG
JO3177B1 (ar) * 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EP2739272A1 (en) * 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
KR101940840B1 (ko) 2011-08-10 2019-01-21 다이이찌 산쿄 가부시키가이샤 디아민 유도체 함유 의약 조성물
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
BR112015016189A8 (pt) 2013-01-08 2019-10-22 Pathologica Llc usos de metilglioxal bis (guanilhidrazona) (“mgbg”), uso de metilglioxal bis (guanilhidrazona) (“mgbg”) e um agente e composição farmacêutica
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
WO2015015254A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2974375A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
WO2022162409A1 (en) * 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators
AU2022214268A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
ATE172711T1 (de) 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
KR100358922B1 (ko) 1994-08-22 2003-01-24 미쯔비시 웰 파마 가부시키가이샤 벤젠화합물및그의의약으로서의용도
EP0812588B1 (en) 1995-12-28 2004-10-13 Mitsubishi Pharma Corporation Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
WO1998037875A1 (fr) * 1997-02-27 1998-09-03 Yoshitomi Pharmaceutical Industries, Ltd. Composition medicamenteuse
JP4045364B2 (ja) * 1997-04-04 2008-02-13 田辺三菱製薬株式会社 ２−アミノプロパン−１，３−ジオール化合物、その医薬としての用途およびその合成中間体
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
JP4012823B2 (ja) 2001-03-26 2007-11-21 ノバルティス アクチエンゲゼルシャフト ２−アミノ−誘導体
US7521192B2 (en) * 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003020313A1 (en) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
EP1431275B1 (en) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
PT1431284E (pt) 2001-09-27 2008-01-21 Kyorin Seiyaku Kk Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
CA2472715A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
EP1575964B1 (en) 2002-01-18 2009-11-11 Merck & Co., Inc. N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
KR101178318B1 (ko) * 2004-07-16 2012-08-29 교린 세이야꾸 가부시키 가이샤 효과적인 의약의 사용법 및 부작용 발현의 방어에 관한방법

Also Published As

Publication number Publication date
FR11C0036I2 (fr) 2023-12-29
HUS1100016I1 (hu) 2016-08-29
NZ586280A (en) 2011-12-22
JP2013177404A (ja) 2013-09-09
IE20040246A1 (en) 2004-12-15
FR2854073A1 (fr) 2004-10-29
EP2008650A3 (en) 2011-04-27
SG175449A1 (en) 2011-11-28
KR20050121712A (ko) 2005-12-27
CY1110260T1 (el) 2014-04-09
AU2004228929B2 (en) 2008-02-07
US20190175527A1 (en) 2019-06-13
MA27729A1 (fr) 2006-01-02
US20090203798A1 (en) 2009-08-13
AU2004228929A1 (en) 2004-10-21
AR043987A1 (es) 2005-08-17
EP2316431B1 (en) 2015-09-30
HUE028247T2 (en) 2016-12-28
US20110105620A1 (en) 2011-05-05
RU2475236C2 (ru) 2013-02-20
WO2004089341A1 (en) 2004-10-21
IL242037A0 (en) 2015-11-30
BRPI0409250B8 (pt) 2022-01-18
HK1091114A1 (en) 2007-01-12
JP2004307506A (ja) 2004-11-04
ECSP056090A (es) 2006-03-01
ZA200507394B (en) 2007-03-28
EP2769713A1 (en) 2014-08-27
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
US8324283B2 (en) 2012-12-04
US20170290787A1 (en) 2017-10-12
RU2010147000A (ru) 2012-08-10
NZ542622A (en) 2009-01-31
PE20130200A1 (es) 2013-03-09
CY1117071T1 (el) 2017-04-05
LU91867I2 (fr) 2011-11-08
GR20040100121A (el) 2004-12-17
ITMI20040682A1 (it) 2004-07-06
DE102004016947A1 (de) 2004-10-21
NO2011016I2 (no) 2012-08-27
CY2011013I1 (el) 2014-04-09
NO334116B1 (no) 2013-12-16
KR20120101148A (ko) 2012-09-12
AT504853A2 (de) 2008-08-15
EP1613288A1 (en) 2006-01-11
KR101367574B1 (ko) 2014-02-25
ES2228282A1 (es) 2005-04-01
CL2004000745A1 (es) 2005-02-11
BRPI0409250B1 (pt) 2017-07-11
GR1005052B (el) 2005-11-30
ES2320767T3 (es) 2009-05-28
IL197578A0 (en) 2011-07-31
IS8885A (is) 2010-02-25
DK2316431T3 (en) 2016-01-11
HRP20050886B1 (en) 2011-01-31
HRP20100600A2 (hr) 2011-03-31
US20080311188A1 (en) 2008-12-18
PL1613288T3 (pl) 2009-07-31
RU2010146697A (ru) 2012-05-27
PE20050396A1 (es) 2005-07-05
PE20150676A1 (es) 2015-05-17
BE2011C030I2 (enExample) 2023-03-07
HRP20100601B1 (hr) 2016-12-02
PE20090743A1 (es) 2009-07-17
TNSN05256A1 (en) 2007-07-10
ES2556947T3 (es) 2016-01-21
DE122011100047I1 (de) 2011-12-15
RU2358716C2 (ru) 2009-06-20
AT501681B1 (de) 2012-04-15
US20130108675A1 (en) 2013-05-02
DE602004017847D1 (de) 2009-01-02
JP2011006461A (ja) 2011-01-13
PT1613288E (pt) 2009-02-25
CA2707750A1 (en) 2004-10-21
ES2228282B1 (es) 2006-02-16
CA2521325A1 (en) 2004-10-21
NZ592339A (en) 2012-09-28
MY141249A (en) 2010-03-31
HRP20100601A2 (hr) 2011-03-31
IL197578A (en) 2015-10-29
KR20110005320A (ko) 2011-01-17
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
EP2319502A1 (en) 2011-05-11
FR11C0036I1 (fr) 2011-10-14
TW200503784A (en) 2005-02-01
NO2011016I1 (no) 2011-09-19
US20060275357A1 (en) 2006-12-07
US20220031609A1 (en) 2022-02-03
CN1767819A (zh) 2006-05-03
CN1767819B (zh) 2010-07-28
TWI332847B (en) 2010-11-11
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
AR078781A2 (es) 2011-11-30
US20140255497A1 (en) 2014-09-11
SI2316431T1 (sl) 2016-04-29
GB2400318B (en) 2005-08-10
BRPI0409250A (pt) 2006-03-28
SI1613288T1 (sl) 2009-04-30
HRP20050886A2 (en) 2006-11-30
IL170888A (en) 2010-06-16
NO329332B1 (no) 2010-09-27
EP1613288B1 (en) 2008-11-19
CY2011013I2 (el) 2014-04-09
US20140011885A1 (en) 2014-01-09
DE202004021680U1 (de) 2010-04-22
GB2400318A (en) 2004-10-13
IS8114A (is) 2005-11-01
JP5543298B2 (ja) 2014-07-09
RU2475237C2 (ru) 2013-02-20
EP2008650A2 (en) 2008-12-31
MXPA05010860A (es) 2006-05-25
DK1613288T3 (da) 2009-03-23
AR078782A2 (es) 2011-11-30
US20200237690A1 (en) 2020-07-30
ATE414508T1 (de) 2008-12-15
GB0407819D0 (en) 2004-05-12
RU2005134173A (ru) 2006-09-10
AT501681A1 (de) 2006-10-15
LU91867I9 (enExample) 2019-01-03
PE20131352A1 (es) 2013-11-14
IS2682B (is) 2010-10-15
RU2009105403A (ru) 2010-08-27
NO20100250L (no) 2006-01-09
NO335120B1 (no) 2014-09-22
HK1155647A1 (en) 2012-05-25
JP5495467B2 (ja) 2014-05-21
NO20055231D0 (no) 2005-11-07
RU2012148593A (ru) 2014-05-20
NO20131287L (no) 2006-01-09
CN101797241A (zh) 2010-08-11
CA2521325C (en) 2010-09-14

Similar Documents

Publication Publication Date Title
FR2854073B1 (fr) Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
NO20081218L (no) Flytende formuleringer
DE60131703D1 (de) Orale feste pharmazeutische Zusammensetzungen zur pH-abhängig mehrphasigen Freisetzung
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
PT1506185E (pt) Compostos novos e sua utilizacao
FR2850576B1 (fr) Composition comprenant un melange de principes actifs, et procede de preparation
EP1648697A4 (en) METHOD FOR INCREASING CAPACITY IN AN AUTOMATIC CLINICAL ANALYZER BY USING A MODULAR REAGENT ABUTMENT
FR2867682B1 (fr) Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
WO2008060546A3 (en) Oral formulations
NO20064808L (no) Orale matrixformuleringer med licarbazepin
NO20064783L (no) Opplosningstabeletter med licarbazepin
TH87290A (th) สารองค์ประกอบทางเภสัชกรรมชนิดใหม่ที่ประกอบด้วยเลเวไทราซีแทม และกระบวนการสำหรับการเตรียมสารนั้น
DK1847259T3 (da) Polyxamerer som smøremiddel til farmaceutiske sammensætningen indeholdende thieno[3,2-c]pyridin-derivater

Legal Events

Date Code Title Description
CA Change of address

Effective date: 20130703

CD Change of name or company name

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP

Effective date: 20130703

Owner name: NOVARTIS AG, CH

Effective date: 20130703

TQ Partial transmission of property

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP

Effective date: 20130703

Owner name: NOVARTIS AG, CH

Effective date: 20130703

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20